While multiple biomarkers have been advanced to better describe the activity of checkpoint immunotherapy, notably tumor mutational burden (TMB), a biological predictor to an anti-cancer immune response is the elaboration of IFN-γ and the development of T cell-inflamed tumor microenvironment. Here, IFNG is linked to neoplasm.